Current studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are showing encouraging effects in treating excess mass and type non-insulin-dependent diabetes. Preclinical evidence suggest a unique https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/